The Nobel Prize in Physiology or Medicine 2013
7 October 2013 | By Nobel Prize
The 2013 Nobel Prize honours three scientists who have solved the mystery of how the cell organizes its transport system...
List view / Grid view
News
Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
Amgen presents nearly two dozen abstracts from Romosozumab and Prolia® (Denosumab) at ASBMR
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
New Tecfidera® (Dimethyl Fumarate) data show stustained efficacy and long-term safety in a broad range of Multiple Sclerosis
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
New Tysabri® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
3 October 2013 | By Biogen Idec
“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease..."
Amgen and AstraZeneca highlight data to be presented at 22nd congress of the European Academy of Dermatology and Venereology
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
Pfizer Inc. announces FDA approval of DUAVEETM for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis
3 October 2013 | By Pfizer Inc.
“The approval of DUAVEE, an important, novel and effective treatment, presents a new opportunity for women..."
Oral apremilast significantly improved nail and scalp psoriasis and health-related quality of life measures in phase III esteem 1 study
3 October 2013 | By Celgene
Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...
AbbVie presents phase II data evaluating the efficacy of Humira® in patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin disease
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
Johnson & Johnson innovation celebrates life science innovation
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
Teva announces favorable ruling on COPAXONE patent litigation in the Netherlands
3 October 2013 | By Teva Pharmaceutical Industries Ltd
Teva believes unpredictable differences between a proposed generic product and COPAXONE® could lead to immunogenic effects in patients...
